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Introduction
The practice of medicine has traditionally been devoted to healing and
improvement of health by the prevention, cure, and management of
disease. In recent years, this goal has been obscured with the widespread
practice of surgical abortion-on-demand and the use of drugs and devices
which cause destruction of the unborn baby (embryo or fetus).
The prescribing of abortifacient drugs and devices by physicians
conflicts with the generally accepted code of medical ethics, as outlined in
the Hippocratic Oath: I
I will neither give a deadly drug to anybody if asked for it , nor will I make a
suggestion to this effect. Similarly, I will not give to a woman an abortive remedy.
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Since abortifacient drugs and devices carry a federal legend, i.e.,
"prescription only," the pharmacist has become linked to the dispensing of
drugs which cause death of the unborn child.
This paper reviews the currently marketed and investigational
abortifacient drugs and devices and discusses the impact ofthese drugs and
devices on health care personnel.
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Figure I . The process of becoming pregnant (Reprinted with permission. Kippley. J. and S.
The Art of Natural Family Planning, ed. 3. Couple to Couple League. Cincinnati. 1984)

Basic Reproductive Physiology

Figure I presents a simplified view of the female internal reproductive
organs.
Eggs , or ova, develop in ovarian follicles for release approximately once
a month , in a process called ovulation. Most women release only one egg
per cycle. After ovulation the ovum travels from the ovary into the
Fallopian tube. If sexual intercourse (coitus) has occurred , the sperm
travel through the opening of the uterus, the cervix, through the uterus and
into the Fallopian tubes, where fertilization of the ovum occurs.
Following ovulation the ovarian follicle becomes the corpus luteum
(Latin, "yellow body") and secretes the hormone progesterone.
Progesterone maintains the lining of the inner wall of the uterus, the
endometrium, in preparation for pregnancy. If the egg has been fertilized
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with sperm, it implants in the endometrium five to nine days following
fertilization. The fertilized egg then produces a hormone called Human
Chorionic Gonadotropin (HCG) which stimulates the corpus luteum to
contjnue producing progesterone, thus preventing the sloughing of the
endometrium in menstruation. (HCG is the substance which is detected in
most pregnancy tests .) This HCG-stimulated production of progesterone
by the corpus luteum will continue for several months, until the placenta
begins production of progesterone.
Abortifacient Drugs and Devices
1. Sodium Chloride 20% (Abbott)
This preparation of hypertonic saline is used to induce fetal death and
abortion during the second trimester, preferably 16-22 weeks gestation. 2
The saline is administered through a large needle which is inserted
through the abdominal wall of the mother into the baby's amniotic sac.
Praior to injection ofthe hypertonic saline, amniotic fluid is removed, and
an equivalent volume of saline is replaced into the amniotic sac ("saline
amniocentesis"). Over the next several hours the baby breathes and
swallows the saline, is poisoned , which results in struggling and sometimes
convulsions ofthe baby. About 24 hours after administration of the saline,
the mother usually begins labor and will deliver a dead baby)
This method of abortion is sometimes termed "salt poisoning" abortion,
due to the mechanism of action of the chemical. Acute hypernatremia, or
salt poisoning, with generalized vasodilation, edema, congestion,
hemorrhage, and shock lead to the death of the baby.4 Additionally, the
corrosive salt solution often burns the baby's skin , resulting in the outer
skin layers being stripped away.
Extrapolation of Centers for Disease Control figures indicates that
approximately 22,000 saline induced abortions were performed annually
in the United States in the few years preceding 1983. 5 However, the sole
producer of 20% saline, Abbott Laboratories, has recently ceased
production of this product. 6 Some feel that this decision is the result of
boycotts of Abbott's monoclonal antibody pregnancy tests by over 2,000
independent pro-life crisis pregnancy centers, e.g., Heartbeat, Birthright
(USA), and those operated by the Christian Action CounciJ.7

2. Prostaglandins
This class of autacoids is one of the most ubiquitous in the body, with a
wide variety of physiological actions on various tissues and systems. Of
interest here are the effects which prostaglandins exert on the uterine
musculature, specifically those found most abundantly in the uterus,
menstrual, and amniotic fluid , the E and F types (PGE2 and PGFs).
The uterine musculature in the pregnant woman becomes more
responsive to the contractile stimulating properties of PGE2and the PG Fs. It
is also known that in the pregnant woman the prostaglandin concentrations
rise in maternal and umbilical cord blood , and in amniotic fluid. 8 ,9
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Unfortunately, these naturally occurring substances (prostaglandins)
which have the physiological purpose to facilitate the birth of a baby, can
also be used medically to kill the same baby by abortion.
The prostaglandin preparations with the licensed indication for use in
mid-trimester abortion are carboprost tromethamine, dinoprost tromethamine, and dinoprostone , all manufactured by Upjohn.
Carboprost tromethamine (PROSTIN / 15 M; name changed to HE MABATE in December, 1988 10 ) is a solution containing 0.25 mg of carboprost
(I5-methyl PG F2a) per ml for intramuscular injection and is recommended for abortion at 13-20 weeks gestation, or for refractory
postpartum uterine bleeding. Dinoprost tromethamine (PROSTIN F2
ALPHA) is a solution containing 5 mg of PGF2a per ml for intraamniotic
injection and is indicated to induce abortion at 16-20 weeks gestation.
(Upjohn ceased production of this product in 1988; however, stock is still
available in various hospitals or from drug wholesalers. 10) Dinoprostone
(PROSTIN E2) is available as a vaginal suppository containing 20 mg of
PGE2 and is recommended for abortion at 12-20 weeks gestation.8 ,9,11
Since these prostaglandins do not have a direct toxic effect on the
unborn child, it is not uncommon for a baby to be aborted who is still alive,
especially in later gestational ages. This has been reported as a
"complication" of prostaglandin abortions. These live babies are either left
to die, or are purposely suffocated.
A recently licensed orally active synthetic analogue of PGEI ,
misoprostol (CYTOTEC, Searle) inhibits gastric acid secretion, having as
its approved use the treatment of gastric ulcers , and as an adjunct in
patients on long-term therapy with non-steroidal anti-inflammatory
agents. 1213
Natio~al pro-life groups were unsuccessful in efforts to see that
misoprostol did not receive FDA approval for use in the U.S. These efforts
were based on the common and serious side-effect of misoprostol to ca use a
chemical abortion at low doses. The manufacturer of misoprostol, G. D.
Searle, will be required to post a warning on its packaging that the drug can
cause miscarriages when taken by pregnant women, and that physicians
should test women for pregnancy before prescribing misoprostol. 13
The prominence of this warning is of grave concern to the pro-life
community due to the certainty that the drug will be used by women as a
"do-it-yourself' abortion. It has been suggested that misoprostol will
become a street drug because there are no other specifically abortifacient
drugs which are effective perorally.14 With regard to the possibility of
physicians prescribing misoprostol for the unapproved use of causing an
abortion , a Searle spokesman has stated that there was "nothing" to
prevent physicians from using CYTOTEC to cause an abortion , if it is
available on the U.S . market. IS
3. Intrauterine Devices (IUD)
The IUD is a foreign body, usually made ofa non-reactive plastic, which
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is inserted into the uterus for birth control purposes. Some of the devices
are impregnated with progesterone (PROGEST ASERT, Alza) or copper
(CU-7, Searle), which increases the efficacy of the IUD .
It is hypothesized that there are two mechanisms by which the IUD
prevents pregnancy. One is by alteration of sperm motility, and the other is
by prevention of implantation of the fertilized ovum, both mechanisms
due to a so-called "foreign body reaction," or inflammation, within the
uterine cavity. More reports substantiate the latter mechanism of action,
i.e. , abortifacient. The IUD does not seem to interfere with the menstrual
cycle or ovulation. 16 - 18
The IUD can cause serious complications, including, hemorrhage,
pelvic infection , and perforation of the uterus, all having the potential to
produce permanent sterility or death . In fact it is advised that a woman
who may wish to bear children in the future should not use an IUD.19
A. H . Robins, the manufacturer of an early IUD, the DALKON
SHIELD, declared Chapter II bankruptcy in August, 1985 to protect
itself from women seeking substantial monetary damages because of
medical complications related to their use of the IUD. Prior to the recent
merger of A. H. Robins with American Home Products, a federal judge
required Robins to appropriate $100 million which would cover
administrative costs of a "DALKON SHIELD Trust Fund", which is
expected to grow to $2.48 billion. This fund would help compensate
approximately 200,000 women who have filed lawsuits against A. H .
Robins, claiming they experienced severe , and often permanent, adverse
effects with the DALKON SHIELD.20-21
Similarly, women using other brands of IU Ds have filed la wsuits against
those manufacturers. G . D . Searle was recently ordered to pay $8.7 million
in damages to a woman who suffered "infertility, illnesses, and 'great pain
and suffering and mental anguish' " from its Copper-7 IU D. This case was
one of 800 lawsuits filed across the U.S . relating to this product, with an
additional 1,000 cases being previously settled . Searle was found
"negligent" in failing to notify the Food and Drug Administration about
what the company allegedly knew were potentially serious health risks
with their product. Internal company memos helped to support these
assertions. 22- 25
A new copper impregnated IUD (COPPER T 380 A , ParaGard ,
GynoPharma) was introduced to the U.S. market in June , 1988. 26 -27 At the
time that this IUD was introduced, the PROGEST ASERT (Alza) was the
only IUD available in the U.S ., since other manufacturers had removed
their IUD's from the U.S. market in 1985 and 1986 to avoid possible
litigation. 28 Potential users of this new copper IUD will be required to sign
a seven-page informed consent form before insertion of the IUD. Alza
currently requires this of its PROGESTASERT users .29

4. Oral Contraceptives ("The Pill")
The most popular type of oral contraceptive is the combination
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preparation which contains a synthetic estrogen and progestin. Various
products and manufacturers are available. 3o A woman is instructed to take
one tablet a day on days 1-21 of her cycle. On the remaining cycle days
(22-28) the woman experiences withdrawal bleeding.
These preparations exert their high degree of contraceptive effectivenes
in three ways:
1. The estrogenic component inhibits FSH (follicle stimulating
hormone) secretion from the pituitary, while the progestin inhibits the
release of pituitary LH (luteinizing hormone). These actions have the
individual and combined effect of preventing ovulation.31
2. In the woman who is taking oral contraceptives, the cervical mucus is
thick and hostile to sperm. This is in contrast to the normal, healthy
cycling woman whose cervical mucus is thin , watery , and abundant in
quantity just prior to ovulation. The latter type of cervical mucus is
conducive to longer sperm life and sperm migration, i.e., motility.32,33
3. The third effect of combined oral contraceptives is to alter the
endometrium in such a way that implantation of the fertilized egg (new
life) is made more difficult, if not impossible. In effect, the endometrium
becomes atrophic and unable to support implantation of the fertilized
egg. 34 ,35
At this point one may question the importance of the second and third
actions of oral contraceptives if ovulation is inhibited. Why are these
subsequent actions important?
Inhibition of ovulation was nearly 100% efficient with the early oral
contraceptives which contained a larger dose of estrogen. Reports, which
associated the estrogen component of the preparations with serious
thromboembolic and cardiovascular disorders , resulted in the marketing
of the "low-dose" combination oral contraceptives. These contain a lower
dose of estrogen. Several years of widespread use of the low-dose
preparations have indicated that the cardiovascular risks are reduced with
the use of the low-dose products, but they are not eliminated .35,36
Unfortunately, the lower estrogen dose allows an increased incidence of
breakthrough ovulation, specifically in 2-5 % of cyclesY However, the
alteration of the endometrium, making it hostile to implantation by the
fertilized egg, provides a back-up abortifacient method to prevent
pregnancy. This is the basis for which selected pro-life organizations object
to the use of oral contraceptives.
In a press release dated April 14, 1988 38 the U.S. Department of Health
and Human Services announced that the three manufacturers of high-dose
(75-100~g) , estrogen combination oral contraceptive pills had agreed to
remove these drugs from the market. All the remaining combination oral
contraceptives will contain a smaller dose of estrogen (30-50~g), the
so-called "low-dose" preparations. Consequently, all currently marketed
oral contraceptives have the potential to cause abortion as a mechanism to
prevent pregnancy. Despite the use of low-dose combination oral
contraceptives, breakthrough ovulation does occur, and pregnancies have
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res ulted. 39
A second type of oral contraceptive, which is not used to the same exetnt
as the combination type, is the preparation which contains a progestin
alone, the so-called "Minipill." The active ingredient is either 0.35 mg
norethindrone (MICRONOR, Ortho; NOR-QD, Syntex) or 0.075 mg
norgestrel (OVRETTE. Wyeth). These preparations were marketed as
safer alternatives to the combination, estrogen-containing oral contraceptives.
The primary mechanism of action of the progestin-only oral
contraceptives to prevent pregnancy is to cause endometrial atrophy, thus
making i( unlikely that the fertilized egg will implant in the uterine wall.
The quality of cervical mucus and the incidence of ovulation mayor may
not be altered .31 ,4o,41
The numerous risks of oral contraceptives will not be detailed here. All
physicians and pharmacists are aware of these risks, due to the U.S.
government requirement that a Patient Package Insert be dispensed with
each package of birth control pills. However, recently released studies
associate oral contraceptive use with an increased risk of breast cancer. 42 - 44
A Food and Drug Administration (FDA) panel voted Jan. 5, 1989 not to
revise the warning labels on oral contraceptives, but that further study
would be needed on this subject.
A contraceptive skin patch is being developed by Cygnus Research
Corporation. The patch would deliver an estrogen and progestin for
transdermal absorption, thus avoiding first-pass metabolism. Clinical
trials ofthis preparation are expected in late 1989.45 Due to the lower doses
of hormones in this investigational product, it is assumed that it will also
have the potential to cause abortion in a small number of cycles , in a
manner similar to the other combination oral contraceptives.

5. Long-Acting Progestins
Medroxyprogesterone acetate (DEPO-PROVERA , Upjohn) is the only
product currently licensed in the U.S . in this category. A dose of 150 mg is
injected intramuscularly once every three months.
The FDA-authorized labeled indication for this product is to treat
inoperable and metastatic endometrial or renal carcinoma. Due to its
potential for causing side effects and permanent infertility, the drug is not
authorized by the FDA as a contraceptive. However, this unlabeled use
persists. The manufacturer of DEPO-PROVERA, Upjohn , is currently
involved in litigation for severe side effects which allegedly occurred from
use of this drug. 46
A preparation of levonorgestrel (NORPLANT, Wyeth) , formulated
within six one-inch polydimethylsiloxane capsules , is currently being
tested by the Population Council in New York for potential marketing in
the U.S . Based on early clinical trials the drug would be administered
subdermally through a 10 or II gauge trocar in a fan-shaped pattern into a
3 mm skin incision. Contraceptive effectiveness would be for up to five
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years. 47 - 50
Two preparations of long-acting progestins, in combination with
estrogens, which are administered by intramuscular injection every two to
six months are dihydroprogesterone acetophenide with estradiol
enanthate (DELADROXATE, Squibb) and medroxyprogesterone acetate
with estradiol cyprionate (CYCLOPROVERA, Upjohn). Although
widely used in foreign countries, they are not available in the U.S.
Other investigational injectable progestins are chlormadinone and
norethisterone enanthate.
The so-called vaginal rings, which contain either norethisterone,
levonorgestrel, or progesterone in various dosage forms, release hormone
on the days in which they are in the vagina, cycle days 5-25, after which
time the ring is removed to allow for withdrawal bleeding. 51
One mechanism of action of long-acting progestins is to block
implantation of the fertilized ovum, similar to the progestin-only oral
contraceptives. 18,35
6. Anti-Progesterones
Anti-progesterones are a new class of investigational, so-called
contraceptives. In reality they are abortifacients. The drugs in this class
include mifepristone (RU 486; Roussel-Ucla£) and Epostane (Sterling).
Contraceptive research has turned to this type of compound in the
search for a "once-a-month" birth control pill. The goal is to find a
preparation which terminates pregnancy within the first five weeks after
fertilization, but would be safer to use than combination oral
contraceptives. For these reasons, inactivation of the corpus luteum (i .e.,
anti-progesterone) would be the preferred mechanism of action. 52
Since mifepristone is closer to being marketed in the U. S. than
Epostane, more detail will be devoted to it in this discussion.
Mifepristone (RU 486)
Acting as a competitive progesterone antagonist at the receptor leve1 53 ,54
mifepristone acts to prevent the implantation of the fertilized ovum into
the endometrium. If implantation has already occurred, the uterine lining
deteriorates, and the baby is lost during menstruation.
In addition to producing abortion by effecting a hostile endometrium
for the unborn child, mifepristone softens the cervix and promotes uterine
contractions, facilitating expulsion of the new life. 55 ,56
Mifepristone is correctly referred to as a "contragestive" ("contra"=
against; "-gestive"=pregnancy), i.e., abortifacient. It is intended for use
within the first 10 weeks of pregnancy, or eight weeks after fertilization.
Initial researchers proposed a dosage schedule of a few days every
month. If the woman was pregnant, the baby would be aborted "naturally"
in a menstrual period. If the woman was not pregnant, but her egg had
been fertilized and was on its way to the uterus for implantation,
mifepristone would cause the endometrium to become hostile to
implantation. (Recall that progesterone is necessary for maintenance of
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the endometrium during the time between ovulation and menstruation in
the non-pregnant woman, and during early pregnancy in the pregnant
woman). Mifepristone does not prevent ovulation or fertilization.
Mifepristone was licensed for use in France and China in September,
1988. French authorities have stipulated that abortion with this drug must
be under the supervision of medical specialists in one of 350 hospital clinics
to whom the drug will be distributed.
The abortion method includes three phases. The first phase is
administration of three-200 mg mifepristone tablets (costing the French
equivalent of $80.00) at a clinic. One and one-half to two days later the
woman returns to the clinic for prostaglandin administration, either by
injection or vaginal suppository. (Reports on clinical trials in Europe have
stated that sulprostone (Schering A. G. of Berlin, W. Germany) was the
prostaglandin used, which produces strong uterine contractions.) The
third phase in the abortion procedure involves a return visit to the clinic to
verify that the embryo has been completely expelled . If the abortion was
incomplete, a dilatation and curettage would be performed. 57 - 59
Clinical testing in the U.S. is being conducted at the University of
Southern California (USC) . Thirty women have received the combination
of mifepristone and prostaglandin injections. These tests are described as a
"second-stage FDA trial to determine correct dosage at different weeks of
pregnancy."
The investigators at USC were reported to say that their work is being
funded by the Population Council in New York. However, a
representative of the Population Council was quoted as saying that past
research on mifepristone at USC has been funded , but that the current
work is not being funded by the Council. 60
The most serious adverse effect of mifepristone is heavy, prolonged
bleeding, which can be as little in quantity as about three times an average
menstrual period , lasting for two weeks, similar to an uncomplicated
miscarriage, or can last as long as four to six weeks. A small number of
women have required blood transfusions. 61 While this bleeding should not
present a serious problem in the present, tightly-controlled use in France
and China, once this drug reaches use in Third World countries, these
controls will no longer exist. A poor woman in these countries would most
probably receive mifepristone, and return home to her remote village,
where medical care and availability of transfusions are absent.
A second complication of mifepristone use it that its abortive
effectiveness is only 80-95 %. There are questions whether unborn babies
who survive attempted abortion with mifepristone will develop normally
throughout the remainder of their gestation , or, if the introduction of
mifepristone by the pharmaceutical industry could make the thalidomide
experience seem small by comparison. 62
A highly-publicized chain of events occurred in October, 1988
concerning the manufacturer of mifepristone , Roussel-Uclaf. On Oct. 21
the company's management committee voted to suspend distribution of
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the drug, fearing boycotts and damage to employee morale . On Oct. 26,
the company informed the press of its decision to remove mifepristone
from the market, only four weeks after it had been approved for use .
Within two days, the French Health Minister ordered Roussel-Velaf to
reverse its decision to remove the drug, threatening the company with
transfer of the patent for mifepristone to another company. The
government of France owns a 36.25% financial share of Roussel-Velaf,
and is authorized to make such transfers "for the public good." Pressured
by this threat, and a petition of over 2000 signatures obtained at the then
convened World Congress of Gynecology and Obstetrics in Rio de Janeiro
opposing Roussel's decision to cease production of mifepristone, the
company reversed its decision , and resumed distribution of the drug. 58
Some involved in mifepristone research refer to the drug as a medical
"menstrual regulator", which tends to mask its abortifacient mechanism of
action. Other misleading terms , intended for the lay public, to describe
mifepristone and other investigational abortion-causing drugs are:
antiprogestin, contragestion, menses regulator, menses inducer, postcoital
contraception, interceptive contraception, and post-fertilization antifertility .
Newspaper reports have indicated that sometime in the early 1990s the
V.S. can expect marketing of mifepristone. Roussel-Velaf, however, is
having difficulty finding an American company to shoulder the potential
liability from introduction of this product. In an April, 1987 letter to
Pharmacists for Life, the assistant director of the Scientific Services
Department of Hoechst-Roussel Pharmaceuticals Inc. stated:
In accord with our contracts, Roussel-Velaf had offered Hoeschst Roussel
Pharmaceuticals Inc. the option for RV 486 in the V.S . We have deelined that
option. As to whether Roussel-Velaf will license another pharmaceutical
company to market RV 486 in the V.S., we do not know. But we can assure you
the Hoeschst-Roussel Pharmaceuticals Inc . will not be involved with this
compound.

Due to the past funding of mifepristone research in the V. S. by the New
York-based private research center, the Population Council, there have
been reports that the drug would be marketed by a company which would
shoulder the liability and predictable protests and boycotts by the pro-life
community. For example, it has been stated that GynoPharma was
created for the marketing of the Copper T 380 A I V D for the Population
Council. 63
Similar to concerns about misoprostol, there have been concerns
expressed about the potential "black market" for mifepristone. 64 ,65 It has
already been reported that, under recently adopted FDA guidelines,
mifepristone may be purchased from overseas sources for use in the V.S .66
Epostane

A second investigational anti-progesterone drug is Epostane. While
both mifepristone and Epostane are anti-progesterones, their mechanisms
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of action are different. Whereas mifepristone works at the level of the
progesterone receptor, Epostane is a competitive inhibitor of 3betahydroxysteroid dehydrogenase, the enzyme which converts pregnenolone
to progesterone.67 ,68
Epostane, taken perorally, has been recommended for use in
conjunction with a prostaglandin (PGE2) vaginal suppository to cause
abortion. Since Epostane lowers the blood levels of progesterone, thereby
making the uterus more sensitive to the action of prostaglandins,
investigators hope that this combination will decrease the amount of
prostaglandin which is needed for abortion. This is "desirable" for the
patient because the side effects of the prostaglandin, e.g., uterine pain and
gastrointestinal upset, will be avoided. 69
Marketing of Epostane in the U.S . does not appear imminent. Sterling
Drug Company, the owner of Epostane, has recently been acquired by
Eastman Kodak. In a letter to the president of Pharmacists for Life, dated
Jan. 16, 1989, the Director of Communications for Sterling Drug Co. has
written:
Approximately two years ago , the Sterling Board of Directors decided that
Epostane was not consistent with the company's goals and clinical trials were
terminated, including any you may have seen referred (to) recently in the scientific
or lay literature.
Accordingly, Sterling will not develop or license this compound for human use.
We will not supply material for clinical trials. We are not doing, nor do we intend
to initiate, any research in this area.

7. Abortion Vaccine
The Task Force on Birth Control Vaccines of the World Health
Organization Special Program of Research, Development and Research
Training in Human Reproduction is sponsoring human testing of an
anti-HCG vaccine. The mechanism by which this vaccine would cause
abortion is by destruction of the hormone (HCG) which the fertilized
ovum (unborn baby) produces to signal the corpus luteum to continue to
produce progesterone. Again, there is seen an anti-progesterone type of
effect, i.e. , preventing implantation of the fertilized egg into the womb .
Sandoz Pharmaceuticals has acted as partial financier of this new
vaccine.7o
Conscience Clause
Due to the marketing, and introduction, of new abortion-causing drugs,
a serious dilemma has arisen for the pharmacy profession. Since human
life begins when the male sperm and female ovum unite, a pharmacist who
has convictions that destruction of this human life is wrong may find
him- ( herself unable to work as a pharmacist, without serious compromise
of his ( her moral and ethical standards. Could a pharmacist be fired for
refusing to dispense oral contraceptives in a retail setting, or PGF20~ in a
hospital setting?
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The first situation has already occurred . An April 10, 1987 article in the
Montreal Gazette (Associated Press) carried the headline: "Two
pharmacists fired for refusing to dispense the Pill on moral grounds ." The
pharmacists were employed at Safeway stores, and were indeed fired for
refusing to dispense oral contraceptives. Fortunately, the two pharmacists
have been able to gain employment at other locations, but are now
required to commute considerable distances from their homes .
Several pharmacists around the country who operate their own
pharmacies have already stopped dispensing oral contraceptives. This is a
courageous move for an independent businessman. Several of these
pharmacy owners have sent letters to their customers explaining their
decision.
The 1973 Roe vs. Wade U.S. Supreme Court decision , which legalized
abortion (throughout the entire nine months of pregnancy) in all 50 states
was based on a purported "right to privacy". We were told that the decision
for a woman to kill her unborn child would now be a " private" matter
between her and her physician.
In the 16 years , and over 24 million unborn babies killed in the U.S .
alone, since 1973, it is evident that abortion is not private. First, those
wanting abortions wanted others to pay for them , through health
insurance premiums or taxes . Second, nurses in hospitals were being
forced to assist in abortion procedures, for fear of losing their jobs.
Likewise, medical students and residents were being coerced into
performing abortions. In fact , some U.S. medical schools and hospitals
required that all physicians who desired positions as obstetrical residents
must be willing to perform abortions. The Civil Rights Restoration Act
(Grove City), passed by the U.S. Congress in early 1988 , would have also
required all hospitals and medical schools to perform abortions if the
institutions received any federal funds , if not for he addition of an
amendment which was added to make the Act "abortion-neutral".
At the present time pharmacists seem to be most at risk to lose their jobs
for refusing to take part in abortions, when compared to other health care
professionals. A national pro-life pharmacists' organization, Pharmacists
for Life, has drafted the "Model Pharmacist's Conscience Clause", which
is being submitted to professional associations , employers, a nd state
pharmacy boards for possible adoption. The text of this cla use a ppears
below:
Any person being a dul y licen sed pharmacist, who shall object on personal,
ethical, moral or religi ous ground s, to the performance of any act or o mission of
any act in the normal course of professional dispensing or performance, right s of
conscience will be respected .
Further, such a refusal to perfo rm any act or the omission of a ny act based
upon such a claim of conscience, shall not form the basis of any claim for damages
or any recriminatory or discriminatory action against such person .
Any such person making such a claim of conscience, or who sta tes a willingness
or intention to make such a claim of conscience , shall not be denied employment ,
or terminated from employment , or discriminated against in any manner related
to employment because of such a claim of conscience.

August, 1990

61

The Center for the Rights of the Terminally III is another organization
to recently draft a "Resolution to Protect the Rights of Conscience of
Health Care Personnel."71
Section 4731.91 of the Ohio Revised Code currently protects nurses,
physicians, and institutions in their right to refuse participation in
abortion proced ures. Onlya test court case will determine if such a la w also
applies to registered pharmacists.
Based on the dismissal of the two pharmacists in the state of
Washington, pharmacists need such a conscience clause in their
employment contracts, which will protect them from being terminated
from their jobs for refusing to dispense drugs which kill unborn children.
Nurses and physicians are now able to be excused from involvement in
abortion procedures. 72 ,73 Pharmacists should have this same right.
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Table 1
MEDICAL ABORTIFACIENTS
Generic Name
1.

Salt

Sodium chloride 20%

2.

Prostaglandins

Dinoprost tromethamine

nade Name

Manufacturer

Abbott l
PROSTINF2

Upjohn

Dinoprosto ne

PROSTINE2

Upjohn

Carboprost tromethamine

PROSTIN 151M
(name changed to
HEMABATE,
December, 1988)

Upjohn

Misoprostol

CYTOTEC

Searle

ALPHA l

Sulprostone2

3.

4.

Schering AG.
(Berlin,
W Germany)

Intrauterine Devices (IUD)

Searle
Thtum-1'l

Searle

PROGESTASERT

Alza

Lippes LoopJ

Ortho

COPPER T 380A (ParaGard)

GynoPhanna

Oral Contraceptives

A Combination lYpe (May cause abo rtion in a small number of cycles.)

Estrogen Component:

ENOVlD,OVULEN,
GYNEX, DEMULEN,
NORETHIN E and M,

Searle

NORINYL, BREVICON
TRI-NORINYL

Syntex

GENORA

Rugby

ORTHO-NOVUM, MODICON

Ortho

OVCON

Mead Johnson

NORLESTRIN, LOESTRIN

Parke-Davis

NELOVA

Warner-Chilcott

OVRAL, NORDETTE,
LO/OVRAL, TRIPHASIL

Wyeth

LEVLEN, TRI-LEVLEN

Berlex

mestranol or ethinyl estradiol

Progestin Component:
norethynodrel,
norethindrone,
norethindrone acetate,

ethynodiol diacetate, or
norgestrel

1 Manufacturer ceased production in 1988.
2 Not licensed in U.S.; used with mifepristone to increase complete abortion rate from 80% to 95%.

3 Not available in U. S.

64

Linacre Quarterly

Table I
MEDICAL ABORTIFACIENTS

(cont)
Generic Ngme

Trade Name

Manufacturer

Norethindrone

MICRONOR

Ortho

NOR-Q.D.

Syntex

Norgestrel

OVRETrE

Wyeth

Medroxyprogesterone acetate

DEPO-PROVERA

Upjohn

Levonorgestrel 3

NORPLANT

Wyeth

Dihydroprogesterone

DELADROXATE3

Squibb

CYCLOPROVERA3

Upjohn

RU486,
investigational
name; MlFEGYNE,

Roussel-Uelaf
(Paris, France)

Oral Contraceptives
(cont)
B. Progestin- Only

("Mini pill")

Long-Acting Progestins

acetophenide with
estradiol enanthate

Medroxyprogesterone
acetate with
estradiol cyprionate
Chlormadinone3,6

Norethisterone3,6
enanthate

Vaginal rings containing
norethisterone,
levonorgestrel,

or progesterone

in various dosage forms 3,6

Anti-Progesterones

Mifepristone4

tradenarne

EpostaneS
Anti-HCG Vaccine6

Sterling
(Eastman Kodak)
World Health
Organization,
primary sponsor;
Sandoz is partial
financier

3 Not available in U.S.
4 Investigational in U.S. Licensed in September, 1988 for use in France and China.
S Not available in U.S. Manufacturer does not intend to market for human use.
6 Inves tigational
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